Disc Medicine (IRON) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Disc Medicine (IRON) has outperformed Supernus Pharmaceuticals (SUPN) over the past year, losing 9.9% versus a loss of 10.4%. Over five years, SUPN leads with a +36.0% price change compared with -45.2% for IRON. Supernus Pharmaceuticals is the larger company by market cap ($2.45 billion vs $2.33 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | SUPN |
|---|---|---|
| Share price | $60.77 | $42.14 |
| Market cap | $2.33B | $2.45B |
| 1-day change | -0.67% | -2.11% |
| YTD return | -22.96% | -13.38% |
| 1-year return | -9.88% | -10.44% |
| 5-year return | -45.18% | +35.98% |
| Forward P/E | — | 9.45 |
| EPS (TTM) | $-6.58 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $718.95M |
| Revenue growth (YoY) | — | +8.63% |
| Net income (latest FY) | — | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | — | -8.66% |
| Net margin | — | -5.36% |
| 52-week high | $99.50 | $59.68 |
| 52-week low | $40.00 | $40.51 |
| Distance from 52-week high | -38.92% | -29.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +69.77% | +46.54% |
| Average volume | 462.73K | 766.52K |
| Shares outstanding | 38.39M | 58.22M |
| Employees | 165 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
IRON vs SUPN FAQ
Which is bigger, Disc Medicine or Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) is larger, with a market capitalization of $2.45B compared with $2.33B for Disc Medicine (IRON).
Which stock has performed better over the past year, IRON or SUPN?
IRON returned -9.88% over the past 12 months, compared with -10.44% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.